| 06/02 | Insider Sell: Apellis Pharmaceuticals |  |
| 25/01 | Insider Sell: Apellis Pharmaceuticals | |
| 09/01 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 | |
| 06/01 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 06/01 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 05/01 | Apellis Pharmaceuticals, Inc. : Change in Directors or Principal Officers (form 8-K) | |
| 05/01 | Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer | |
| 05/01 | Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer | |
| 05/01 | Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer | |
| 04/01 | North American Morning Briefing: Futures Rise -2- | |
| 03/01 | Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference | |
| 03/01 | Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference | |
| 2022 | Apellis Files Marketing Authorization Application With European Medicines Agency for Ex.. | |
| 2022 | Apellis Submits Marketing Authorization Application to the European Medicines Agency fo.. | |
| 2022 | Apellis Submits Marketing Authorization Application to the European Medicines Agency fo.. | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Pharmaceuticals to Present at Upcoming Investor Conferences | |
| 2022 | Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 20.. | |
| 2022 | Apellis Says FDA Accepts Amended New Drug Application for Eye Disease Drug Candidate; S.. | |
| 2022 | Sector Update: Health Care Stocks Advance Pre-Bell Friday | |
| 2022 | Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 20.. | |
| 2022 | Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 20.. | |
| 2022 | North American Morning Briefing: Fed Hopes, China -3- | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Pharmaceuticals Q3 Loss Narrows, Revenue Rises | |
| 2022 | APELLIS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condit.. | |
| 2022 | Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine M.. | |
| 2022 | Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q3 Revenue $22.1M | |
| 2022 | Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results | |
| 2022 | Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 2022 | Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profil.. | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan ND.. | |
| 2022 | Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan ND.. | |
| 2022 | Apellis Pharmaceuticals, Inc. Announces Plans to Submit 24-Month Phase 3 Data to the FD.. | |
| 2022 | Safety Of Intravitreal Pegcetacoplan : 24-month results from the OAKS and DERBY phase 3 tr.. | |
| 2022 | Efficacy Of Intravitreal Pegcetacopl : 24-month results from the phase 3 OAKS and DERBY tr.. | |
| 2022 | Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profil.. | |
| 2022 | Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profil.. | |
| 2022 | Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profil.. | |
| 2022 | Apellis Pharmaceuticals to Host Conference Call on Nov 7 2022 to Discuss Third Quarter .. | |
| 2022 | Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter.. | |
| 2022 | Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter.. | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4) | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi.. | |
| 2022 | Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla.. | |
| 2022 | Safety Of Intravitreal Pegcetacoplan : 24-Month Results from the Phase 3 OAKS and DERBY Tr.. | |
| 2022 | Efficacy Of Intravitreal Pegcetacopl : 24-Month Results from the Phase 3 OAKS and DERBY Tr.. | |
| 2022 | Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year O.. | |
| 2022 | Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla.. | |
| 2022 | Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla.. | |
| 2022 | Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treat.. | |
| 2022 | Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi.. | |
| 2022 | Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi.. | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global H.. | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Pharmaceuticals to Present at Upcoming Investor Conferences | |
| 2022 | Apellis Pharmaceuticals to Present at Upcoming Investor Conferences | |
| 2022 | Analyst recommendations: Nvidia, Thermo Fisher Scientific, Danah.. | |
| 2022 | Apellis Pharmaceuticals : 24-month Phase 3 DERBY and OAKS results Presentation | |
| 2022 | Apellis Pharmaceuticals, Inc. : Other Events (form 8-K) | |
| 2022 | Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacopl.. | |
| 2022 | Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacopl.. | |
| 2022 | Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over.. | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Pharmaceuticals Narrows Q2 Loss, Revenue Rises | |
| 2022 | Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q2 Revenue $16.3M | |
| 2022 | Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q2 Loss $-1.46 | |
| 2022 | Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results | |
| 2022 | APELLIS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condit.. | |
| 2022 | Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results | |
| 2022 | Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six M.. | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 2022 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4.. | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Pharmaceuticals, Inc. : Entry into a Material Definitive Agreement, Unregistered S.. | |
| 2022 | Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarte.. | |
| 2022 | Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarte.. | |
| 2022 | Insider Sell: Apellis Pharmaceuticals | |
| 2022 | Apellis Pharmaceuticals Enters Agreements to Exchange $75.6 Million of Convertible Seni.. | |
| 2022 | Apellis Pharmaceuticals : Announces Agreements to Exchange Approximately $75.6 Million in .. | |
| 2022 | Apellis Pharmaceuticals, Inc. : Entry into a Material Definitive Agreement, Unregistered S.. | |
| 2022 | Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amoun.. | |
| 2022 | Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amoun.. | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (België)
Rapport
